Citations

Showing 10 of 108094 citations.

Flt3 Signaling in B Lymphocyte Development and Humoral Immunity
Medina, Kay L. , Medina, Kay L

Mayo Clinic

International Journal of Molecular Sciences | July 1, 2022 | Volume: 23 | Issue: 13 | Pages: 7289

10.3390/ijms23137289 | PMID 35806293 Get It

The Class III receptor tyrosine kinase Flt3 and its ligand, the Flt3-ligand (FL), play an integral role in regulating the proliferation, differentiation, and survival of multipotent hematopoietic and lymphoid progenitors from which B cell precursors derive in bone marrow (BM). More recently, essential roles for Flt3 signaling in the regulation of peripheral B cell development and affinity maturation have come to light. Experimental findings derived from a multitude of mouse models have reinforced the importance of molecular and cellular regulation of Flt3 and FL in lymphohematopoiesis and adaptive immunity. Here, we provide a comprehensive review of the current state of the knowledge regarding molecular and cellular regulation of Flt3/FL and the roles of Flt3 signaling in hematopoietic stem cell (HSC) activation, lymphoid development, BM B lymphopoiesis, and peripheral B cell development. Cumulatively, the literature has reinforced the importance of Flt3 signaling in B cell development and function. However, it has also identified gaps in the knowledge regarding Flt3-dependent developmental-stage specific gene regulatory circuits essential for steady-state B lymphopoiesis that will be the focus of future studies.
Testing for Dihydropyrimidine Dehydrogenase Deficiency to Individualize 5-Fluorouracil Therapy
Diasio, Robert B. , Offer, Steven M.

Mayo Clinic

Cancers | June 30, 2022 | Volume: 14 | Issue: 13 | Pages: 3207

10.3390/cancers14133207 | PMID 35804978 Get It

Severe adverse events (toxicity) related to the use of the commonly used chemotherapeutic drug 5-fluorouracil (5-FU) affect one in three patients and are the primary reason cited for premature discontinuation of therapy. Deficiency of the 5-FU catabolic enzyme dihydropyrimidine dehydrogenase (DPD, encoded by DPYD) has been recognized for the past 3 decades as a pharmacogenetic syndrome associated with high risk of 5-FU toxicity. An appreciable fraction of patients with DPD deficiency that receive 5-FU-based chemotherapy die as a result of toxicity. In this manuscript, we review recent progress in identifying actionable markers of DPD deficiency and the current status of integrating those markers into the clinical decision-making process. The limitations of currently available tests, as well as the regulatory status of pre-therapeutic DPYD testing, are also discussed.
Utilizing a Referral-Based Procedure Clinic Rotation in Family Medicine Residency
Khera, Kushal D. , Boswell, Christopher L.

Mayo Clinic

PRiMER | June 30, 2022 | Volume: 6 | Issue: No issue available | Pages: No page available

10.22454/primer.2022.962965 | PMID 35812790 Get It

Introduction: Performing clinical procedures is an essential component of family medicine (FM) residency training. A referral-based procedure clinic was established at our institution in 2014, and a yearly 2-week rotation was established for residents. The objective of this study was to determine the effect of a procedure clinic rotation on the numbers of procedures performed during residency training. Methods: We conducted a retrospective review on graduating FM residents from 2009 to 2019. Data collected include type and number of procedures performed each postgraduate year. We analyzed data as mean number of procedures per resident per year. We conducted statistical comparison with Wilcoxon-Mann-Whitney two-sample rank-sum tests. Results: Residents who participated in the procedure clinic rotation performed significantly more dermatologic procedures per year, joint and soft tissue injections and intrauterine device (IUD) insertions and removals, but did not perform significantly more circumcisions, endometrial biopsies, incision and drainages, subdermal contraceptive implant procedures, toenail removals, or vasectomies. Conclusion: The establishment of a 2-week procedure clinic rotation for FM residents was associated with a significant increase in dermatologic procedures, joint and soft tissue injections, and IUD procedures. Further research can explore the impact of this rotation on procedural competency and confidence.
Tranexamic Acid Was Not Associated with Increased Complications in High-Risk Patients with Intertrochanteric Fracture
Spaulding, Aaron , Duncan, Christopher M. , Wilke, Benjamin K. , Pagnano, Mark W. , Abdel, Matthew P. , Porter, Steven B , Spaulding, Aaron , Duncan, Christopher M , Wilke, B K , Pagnano, Mark W , Abdel, Matthew P , Porter, Steven B.

Mayo Clinic

Journal of Bone and Joint Surgery | June 30, 2022 | Volume: 104 | Issue: 13 | Pages: 1138-1147

10.2106/jbjs.21.01389 | PMID 35775092 Get It

Background: For elective total joint arthroplasty, tranexamic acid (TXA) is considered safe and efficacious. However, evidence of TXA’s safety in high-risk patients undergoing nonelective surgery for hip fracture is sparse. This study aimed to assess whether TXA administration to high-risk patients with an intertrochanteric (IT) hip fracture increased the risk of thromboembolic complications or mortality. Methods: All patients treated surgically for IT hip fracture between 2015 and 2019 across 4 hospitals of a single hospital system were considered. High- versus low-risk patients and those receiving TXA versus no TXA treatment were identified. Propensity scores adjusted for risk differences between patient groups with TXA and no TXA administration were calculated for (1) high-risk patients (n = 141) and (2) the entire population (n = 316). Postoperative mortality, deep venous thrombosis (DVT), pulmonary embolism (PE), myocardial infarction (MI), and stroke within 90 days of surgery were evaluated. Results: No association between TXA administration and increased risk of mortality or complications in either group was identified. Specifically, out of 282 matched high-risk patients, no differences in mortality (odds ratio [OR], 0.97 [95% confidence interval (CI), 0.90, 1.05]), DVT (OR, 0.97 [95% CI, 0.93, 1.00]), PE (OR 1.00 [95% CI, 0.95, 1.05]), MI (OR, 1.04 [95% CI, 0.98, 1.10]), or stroke (OR, 1.00 [95% CI, 0.95, 1.05]) were identified. Conclusions: In our review of propensity-matched high-risk patients undergoing surgical repair for IT fracture, we found that TXA administration compared with no TXA administration was not associated with an increased risk of mortality, DVT, PE, MI, or stroke within 90 days of surgery. Level of Evidence: Therapeutic Level IV . See Instructions for Authors for a complete description of levels of evidence.
Characterization of unusual iAMP21 B‐lymphoblastic leukemia (iAMP21‐ALL) from the Mayo Clinic and Children's Oncology Group
Koleilat, Alaa , Smadbeck, James B. , Zepeda‐Mendoza, Cinthya , Williamson, Cynthia M., Golden, Crystal L., Xu, Xinjie , Greipp, Patricia T. , Hoppman, Nicole L., Peterson, Jess F. , Akkari, Yassmine, Tsuchiya, Karen D. , Shago, Mary , Greipp, Patricia T , Ketterling, Rhett P , Peterson, Jess F , Harrison, Christine J , Tsuchiya, Karen D , Baughn, Linda B , Pitel, Beth A. , Ketterling, Rhett P. , Harrison, Christine J. , Baughn, Linda B.

Mayo Clinic

Genes, Chromosomes and Cancer | June 30, 2022 | Volume: 61 | Issue: 12 | Pages: 710-719

10.1002/gcc.23084 | PMID 35771717 Get It

AbstractAcute lymphoblastic leukemia (B‐ALL) with intrachromosomal amplification of chromosome 21 (iAMP21‐ALL) represents a recurrent high‐risk cytogenetic abnormality and accurate identification is critical for appropriate clinical management. Identification of iAMP21‐ALL has historically relied on fluorescence in situ hybridization (FISH) using a RUNX1 probe. Current classification requires ≥ five copies of RUNX1 per cell and ≥ three additional copies of RUNX1 on a single abnormal iAMP21‐chromosome. We sought to evaluate the performance of the RUNX1 probe in the identification of iAMP21‐ALL. This study was a retrospective evaluation of iAMP21‐ALL in the Mayo Clinic and Children's Oncology Group cohorts. Of 207 cases of iAMP21‐ALL, 188 (91%) were classified as “typical” iAMP21‐ALL, while 19 (9%) cases were classified as “unusual” iAMP21‐ALL. The “unusual” iAMP21 cases did not meet the current definition of iAMP21 by FISH but were confirmed to have iAMP21 by chromosomal microarray. Half of the “unusual” iAMP21‐ALL cases had less than five RUNX1 signals, while the remainder had ≥ five RUNX1 signals with some located apart from the abnormal iAMP21‐chromosome. Nine percent of iAMP21‐ALL cases fail to meet the FISH definition of iAMP21‐ALL demonstrating that laboratories are at risk of misidentification of iAMP21‐ALL when relying only on the RUNX1 FISH probe. Incorporation of chromosomal microarray testing circumvents these risks.
Faculty Opinions recommendation of Role of Water in Defining the Structure and Properties of B-Form DNA.
Maher, Jim

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | June 30, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.742212606.793593882 Get It

Works in Progress: Using Administrative Data to Estimate the Prevalence of Progressive Fibrosing Interstitial Lung Disease
Bowman, Willis S., Dempsey, Timothy , Dempsey, Timothy M

Mayo Clinic

Annals of the American Thoracic Society | June 30, 2022 | Volume: 19 | Issue: 7 | Pages: 1095-1097

10.1513/annalsats.202203-276ed | PMID 35772099 Get It

Tumor Mutational Burden Is a Potential Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Patients With Advanced Biliary Tract Cancer
Liddell, S. , Chakrabarti, Sakti , Wintheiser, Grant , Shi, Qian , Tella, Sri Harsha , Jin, Zhaohui , Wookey, Vanessa, Hassan, Hind , Tran, Nguyen H. , Liddell, Savannah S , Wintheiser, Grant A , Zemla, Tyler J, Shi, Qian , Jin, Zhaohui , Wookey, Vanessa B, Tran, Nguyen , Borad, Mitesh J , Mahipal, Amit , Chakrabarti, Sakti , Zemla, Tyler , Borad, Mitesh J. , Mahipal, Amit

Mayo Clinic

JCO Precision Oncology | June 30, 2022 | Volume: No volume available | Issue: 6 | Pages: No page available

10.1200/po.22.00003 | PMID 35772047 Get It

PURPOSE Patients with advanced biliary tract cancers (BTCs) have a dismal prognosis. This multisite, single-institution study analyzed the efficacy and safety of immune checkpoint inhibitors (ICIs) in patients with advanced BTC. MATERIALS AND METHODS The prospectively maintained institutional database was searched for patients with advanced BTC. Electronic medical records of the patients with advanced BTC treated with an ICI that included programmed death-1 or programmed death-ligand 1 blockers were retrospectively reviewed to obtain data on patient characteristics, tumor characteristics including molecular biomarkers, detailed treatment, response characteristics, survival, and toxicities. The analysis included overall response rate, survival, and correlation between survival and molecular biomarkers. RESULTS The institutional database query identified 47 patients with advanced BTC who received at least one dose of an ICI; 11 (24%) patients in the first-line setting and the rest of the patients had refractory disease. The median age of the cohort was 62 years, and 51% were female. The overall response rate was 10.6%, with a disease control rate of 53.2%. The median progression-free survival (PFS) and overall survival were 3.6 months and 6.9 months, respectively. Biomarker analysis revealed improved PFS in patients with tumor mutational burden > 5 mutations per megabase (median PFS: 6.4 v 2.2 months; P = .0027). No unexpected adverse events were observed. CONCLUSION ICIs are well tolerated and have modest antitumor activity in patients with advanced BTC. The study result supports the exploration of tumor mutational burden as a potential predictive biomarker for response to ICIs in patients with advanced BTC.
Modismos de distrés: significado cultural y clínico en poblaciones latinoamericanas
Alarcón, Renato D.

Mayo Clinic

Mente y Cultura | June 30, 2022 | Volume: 3 | Issue: 1 | Pages: 33-40

10.17711/myc.2683-3018.2022.005 Get It

Surgical versus catheter ablation in atrial fibrillation: A systematic review and meta‐analysis of randomized controlled trials
Kanitsoraphan, Chanavuth , Kewcharoen, Jakrin , Sriramoju, Anil, Shanbhag, Anusha , Ko, Nway L. Ko, Barry, Timothy , Vutthikraivit, Wasawat , Shen, Win‐Kuang , Rattanawong, Pattara , Kanitsoraphan, Chanavuth , Kewcharoen, Jakrin , Ko Ko, Nway L, Vutthikraivit, Wasawat , Rattanawong, Pattara , Sriramoju, Anil

Mayo Clinic

Journal of Cardiovascular Electrophysiology | June 30, 2022 | Volume: 33 | Issue: 10 | Pages: 2152-2163

10.1111/jce.15617 | PMID 35771487 Get It

AbstractIntroductionAtrial fibrillation (AF) is the most common cardiac arrhythmia with a high stroke and mortality rate. The video‐assisted thoracoscopic radiofrequency pulmonary vein ablation is a treatment option for patients who fail catheter ablation. Randomized data comparing surgical versus catheter ablation are limited. We performed a meta‐analysis of randomized control trials to explore the outcome efficacy between surgical and catheter radiofrequency pulmonary vein ablation in patients with AF.MethodsWe comprehensively searched the databases of MEDLINE and EMBASE from inception to December 2020. Included studies were published randomized control trials that compared video‐assisted thoracoscopic and catheter radiofrequency pulmonary vein ablation. Data from each study were combined using the fixed‐effects, generic inverse variance method of DerSimonian, and Laird to calculate odds ratios and 95% confidence intervals.ResultsSix studies from November 2013 to 2020 were included in this meta‐analysis involving 511 AF patients (79% paroxysmal) with 263 catheter ablation (mean age 56 ± 3 years) and 248 surgical ablations (mean age 52 ± 4 years). Catheter ablation was associated with increased atrial arrhythmias recurrence when compared to surgical ablation (pooled relative risk = 1.85, 95% confidence interval: 1.44−2.39, p < .001, I2 = 0.0%) but associated with less total major adverse events (pooled relative risk = 0.29, 95% confidence interval: 0.16−0.53, p < .001, I2 = 0.0%). In subgroup analysis, catheter ablation was associated with increased AF recurrence in refractory paroxysmal AF when compared to surgical ablation (pooled relative risk = 2.47, 95% confidence interval: 1.31−4.65, p = .005, I2 = 0.0%) but not in persistent AF (relative risk = 1.09, 95% confidence interval: 0.60−2.0, p = .773).ConclusionCatheter ablation was associated with higher atrial arrhythmia recurrence when compared with surgical ablation. However, our study suggests that the benefit of surgical ablation in patients with persistent AF is unclear. More studies and alternative ablation strategies investigation in persistent AF are warranted.